Drugmakers showed off data on weight loss and diabetes drugs. Also, Oracle announced the general availability of AI documentation assistant for doctors.
The drug developments come amid growing investor interest in the treatment of metabolic diseases and specifically, a buzzy class of medications called GLP-1s
Administrative tasks like paperwork are often burdensome for health-care workers, as nearly 65% of doctors feel like they are a major cause of burnout, according to a Februaryfrom Athenahealth. Physicians spend an average of 15 hours per week outside their normal hours keeping up with the workload, the survey said.
The assistant works alongside Oracle's electronic health record, so doctors can also verbally ask it to pull up information about a patient's medical history, like their latest blood test results, the company said. In other words, doctors can spend less time searching through records to find the relevant information they need.
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Healthy Returns: Eli Lilly, other drugmakers show off encouraging weight loss drug dataDrugmakers showed off data on weight loss and diabetes drugs. Also, Oracle announced the general availability of AI documentation assistant for doctors.
Read more »
Why Eli Lilly shares should be up on its latest news, plus Nvidia keeps rollingEvery weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.
Read more »
Alphabet names Eli Lilly veteran Ashkenazi as CFOAlphabet names Eli Lilly veteran Ashkenazi as CFO
Read more »
Alphabet taps Eli Lilly's Anat Ashkenazi as new CFOThe new Google executive will replace Ruth Porat, who will become president and chief investment officer of the company after nearly a decade as CFO.
Read more »
FDA analysis raises no major concerns about Eli Lilly Alzheimer's drugAn FDA analysis of trial data for Eli Lilly's experimental Alzheimer's drug donanemab released on Thursday revealed no red flags, but raised questions about safety of the treatment for patients with early-stage disease.
Read more »
FDA advisors recommend Eli Lilly's Alzheimer's drug donanemab, paving way for approvalIf approved, Eli Lilly’s donanemab would become the second Alzheimer’s drug of its kind to enter the market after Leqembi from Biogen and Eisai.
Read more »